429 related articles for article (PubMed ID: 20117339)
1. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
Mendoza JL; Abreu MT
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
3. Fecal markers: calprotectin and lactoferrin.
Abraham BP; Kane S
Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
[TBL] [Abstract][Full Text] [Related]
4. Serologic markers in inflammatory bowel disease (IBD).
Nakamura RM; Barry M
MLO Med Lab Obs; 2001 Nov; 33(11):8-15; quiz 16-9. PubMed ID: 11721286
[TBL] [Abstract][Full Text] [Related]
5. [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease].
van den Bergh FA; Kolkman JJ; Russel MG; Vlaskamp RT; Vermes I
Ned Tijdschr Geneeskd; 2003 Nov; 147(48):2360-5. PubMed ID: 14677476
[TBL] [Abstract][Full Text] [Related]
6. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease.
Arai R
Postgrad Med; 2010 Jul; 122(4):177-85. PubMed ID: 20675980
[TBL] [Abstract][Full Text] [Related]
7. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
[TBL] [Abstract][Full Text] [Related]
8. New serologic markers for inflammatory bowel disease diagnosis.
Dotan I
Dig Dis; 2010; 28(3):418-23. PubMed ID: 20926866
[TBL] [Abstract][Full Text] [Related]
9. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of serological markers in inflammatory bowel disease.
Mokrowiecka A; Daniel P; Słomka M; Majak P; Malecka-Panas E
Hepatogastroenterology; 2009; 56(89):162-6. PubMed ID: 19453050
[TBL] [Abstract][Full Text] [Related]
11. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases].
Iijima H; Shinzaki S; Tsujii M; Takehara T
Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
[TBL] [Abstract][Full Text] [Related]
13. [Relevance of serologic studies in inflammatory bowel diseases].
Papp M; Altorjay I; Lakatos PL
Orv Hetil; 2007 May; 148(19):887-96. PubMed ID: 17478404
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
[TBL] [Abstract][Full Text] [Related]
15. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
Olbjørn C; Cvancarova Småstuen M; Thiis-Evensen E; Nakstad B; Vatn MH; Perminow G
Scand J Gastroenterol; 2017 Apr; 52(4):414-419. PubMed ID: 27887202
[TBL] [Abstract][Full Text] [Related]
16. Update of fecal markers of inflammation in inflammatory bowel disease.
Judd TA; Day AS; Lemberg DA; Turner D; Leach ST
J Gastroenterol Hepatol; 2011 Oct; 26(10):1493-9. PubMed ID: 21777275
[TBL] [Abstract][Full Text] [Related]
17. Review of fecal biomarkers in inflammatory bowel disease.
Sutherland AD; Gearry RB; Frizelle FA
Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
[TBL] [Abstract][Full Text] [Related]
18. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
19. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
Caccaro R; D'Incá R; Sturniolo GC
Expert Rev Clin Immunol; 2010 Jul; 6(4):551-8. PubMed ID: 20594128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
